PEDIATRICS Vol. 107 No. 6 June 2001, pp. 1313-1316
Cisapride Associated With QTc Prolongation in Very Low Birth Weight Preterm Infants
Received Jun 6, 2000; accepted Sep 26, 2000.
,
, §, and
From the Divisions of * Pediatric Cardiology and Objective. No systematic study has
been performed to evaluate the effect of cisapride on the QT interval
in premature infants. Cisapride, which has recently been withdrawn by
the Food and Drug Administration and is no longer an approved therapy,
was commonly used for preterm infant care to improve the advance of
enteral feedings and to reduce reflux and associated apnea. Our aim was
to evaluate the effect of recommended doses of cisapride on the QT
interval in this population.
Study Design. Prospective blinded evaluation of
electrocardiogram for QT, JT, QTc, and JTc measurements in 25 preterm
infants before and after cisapride administration.
Results. Twelve of 25 infants (48%) developed
repolarization abnormalities with cisapride administration: 32% of the
infants (8/25) studied had QTc prolongation ( Conclusions. The QTc and JTc interval significantly
prolonged in preterm infants <32 weeks on the recommended dose of
cisapride therapy. A QTc
Neonatal and
Development Medicine, Department of Pediatrics, Stanford University,
Stanford, California; § Netherlands Institute for Brain Research,
Amsterdam, The Netherlands; and the
Leiden University School of
Medicine, Leiden, The Netherlands.
0.450 seconds), whereas
10/25 had JTc prolongation (
0.360 seconds). Preterm infants <32
weeks significantly prolonged their QTc interval from 0.41 ± 0.02 to 0.44 ± 0.02. The QTc and/or JTc was prolonged in 54% of
infants receiving 0.1 mg/kg/dose and 42% receiving 0.2 mg/kg/dose.
0.450 seconds developed in 32% of infants
treated with cisapride, whereas the JTc prolonged in 40%. A
significant percentage of infants (54%) developed prolonged QTc
intervals at a dose of 0.1 mg/kg/dose. From these data we conclude that
there is a higher risk of prolongation of the QTc interval and risk of
arrhythmias with greater prematurity.
This article has been cited by other articles:
![]() |
S. Laer, J.-P. Elshoff, B. Meibohm, J. Weil, T. S. Mir, W. Zhang, and M. Hulpke-Wette Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol Based on Population Pharmacokinetics and Pharmacodynamics in Children With Supraventricular Tachycardia J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1322 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Ariagno, M. Mirmiran, M. M. Adams, A. G. Saporito, A. M. Dubin, and R. B. Baldwin Effect of Position on Sleep, Heart Rate Variability, and QT Interval in Preterm Infants at 1 and 3 Months' Corrected Age Pediatrics, March 1, 2003; 111(3): 622 - 625. [Abstract] [Full Text] [PDF] |
||||







